Bayer Seen Posting €3.93 Billion Q1 EBITDA as $7.25 Billion Roundup Settlement Stays in Focus
Updated
Updated · MarketWatch · May 11
Bayer Seen Posting €3.93 Billion Q1 EBITDA as $7.25 Billion Roundup Settlement Stays in Focus
13 articles · Updated · MarketWatch · May 11
€3.93 billion in first-quarter EBITDA before special items is the consensus for Bayer, down from €4.085 billion a year earlier, on expected sales of €13.42 billion versus €13.74 billion.
The key investor focus is Bayer's effort to contain U.S. Roundup litigation as it awaits a Supreme Court ruling and the outcome of a proposed $7.25 billion settlement covering most current cases.
Last month, Supreme Court justices pressed Bayer on whether it failed to warn consumers that Roundup might cause cancer; Bayer continues to argue the weedkiller is safe and says a favorable ruling would clarify product-liability standards.
Despite the weaker quarter, analysts say Bayer's 2026 guidance for stable currency-adjusted sales and EBITDA still looks intact, helped by limited Middle East exposure, resilient end markets and higher weedkiller prices.
As its multi-billion dollar legal strategy falters, what is Bayer's last resort to escape the crushing Roundup litigation?
Could a Supreme Court loss for Bayer unleash a wave of new lawsuits against countless other federally regulated products?
With top agencies like the WHO and EPA disagreeing, what is the real scientific truth about Roundup and its link to cancer?